Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies [Yahoo! Finance]
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update